Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016;2016:4030476.
doi: 10.1155/2016/4030476. Epub 2016 May 11.

The Effect of Artichoke Leaf Extract on Alanine Aminotransferase and Aspartate Aminotransferase in the Patients With Nonalcoholic Steatohepatitis

Affiliations
Free PMC article

The Effect of Artichoke Leaf Extract on Alanine Aminotransferase and Aspartate Aminotransferase in the Patients With Nonalcoholic Steatohepatitis

Vajiheh Rangboo et al. Int J Hepatol. .
Free PMC article

Abstract

Background. Based on recent basic and clinical investigations, the extract of artichoke (Cynara scolymus) leaf has been revealed to be used for hepatoprotective and cholesterol reducing purposes. We aimed to assess the therapeutic effects of artichoke on biochemical and liver biomarkers in patients with nonalcoholic steatohepatitis (NASH). Methods. In a randomized double blind clinical trial, 60 consecutive patients suffering NASH were randomly assigned to receive Cynara scolymus extract (as 6 tablets per day consisting of 2700 mg extract of the herb) as the intervention group or placebo as the control group for two months. Results. Comparing changes in study markers following interventions showed improvement in liver enzymes. The levels of triglycerides and cholesterol were significantly reduced in the group treated with Cynara scolymus when compared to placebo group. To compare the role of Cynara scolymus use with placebo in changes in study parameters, multivariate linear regression models were employed indicating higher improvement in liver enzymes and also lipid profile particularly triglycerides and total cholesterol following administration of Cynara scolymus in comparison with placebo use. Conclusion. This study sheds light on the potential hepatoprotective activity and hypolipidemic effect of Cynara scolymus in management of NASH. This clinical trial is registered in the IRCT, Iranian Registry of Clinical Trials, by number IRCT2014070218321N1.

Similar articles

See all similar articles

Cited by 4 articles

References

    1. Chalasani N., Younossi Z., Lavine J. E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592–1609. doi: 10.1053/j.gastro.2012.04.001. - DOI - PubMed
    1. Dyson J. K., Anstee Q. M., McPherson S. Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterology. 2014;5(4):277–286. doi: 10.1136/flgastro-2013-100404. - DOI - PMC - PubMed
    1. Machado M. V., Cortez-Pinto H. Non-alcoholic fatty liver disease: what the clinician needs to know. World Journal of Gastroenterology. 2014;20(36):12956–12980. doi: 10.3748/wjg.v20.i36.12956. - DOI - PMC - PubMed
    1. Corrado R. L., Torres D. M., Harrison S. A. Review of treatment options for nonalcoholic fatty liver disease. Medical Clinics of North America. 2014;98(1):55–72. doi: 10.1016/j.mcna.2013.09.001. - DOI - PubMed
    1. Eguchi A., Povero D., Alkhouri N., Feldstein A. E. Novel therapeutic targets for nonalcoholic fatty liver disease. Expert Opinion on Therapeutic Targets. 2013;17(7):773–779. doi: 10.1517/14728222.2013.789502. - DOI - PubMed

LinkOut - more resources

Feedback